| ORIGINAL ARTICLE |
|
| Year : 2022 | Volume
: 19
| Issue : 4 | Page : 230-233 |
|
|
A study on safety and clinical efficacy of COVID-19 vaccines among adults in South India: A cross-sectional study
Huluvadi Shivalingaiah Anwith1, Deena Mariyam2, M Madhusudan3, Ramegowda Chethana1, Hulugappa Lakshmi4
1 Department of Community Medicine, Kempegowda Institute of Medical Sciences, Bangalore, Karnataka, India
2 Department of Medical Intern, Kempegowda Institute of Medical Sciences, Bangalore, Karnataka, India
3 Scientist D (Medical), ICMR-National Centre for Disease Informatics and Research, Bangalore, Karnataka, India
4 Department of Community Medicine, Akash Institute of Medical Sciences and Research Centre, Bangalore, Karnataka, India
Correspondence Address:
Dr. Hulugappa Lakshmi
Department of Community Medicine, Akash Institute of Medical Sciences and Research Centre, Bengaluru, Karnataka
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/am.am_92_22
|
|
|
Introduction: COVID-19 virus caused a pandemic in 2020. Since vaccine was the only modality to combat the pandemic, the development of vaccine was fast tracked and made available within 1 year of detecting the virus. Objective: The objective of this study was to assess the safety and clinical efficacy of the COVID-19 vaccines. Materials and Methods: This was a cross-sectional study conducted between June 2021 and September 2021 in Bengaluru using digital data capture. Data pertaining to sociodemographic profile, details of the vaccine administered, adverse events developing within 7 days of vaccine administration, and breakthrough infection were collected. Descriptive statistics such as frequencies, percentages, and mean and standard deviation were used. Inferential statistics such as the Chi-square test were used to test association. Results: The study involved 103 study participants. Totally 100 (97.08) participants had taken Covishield and 3 (2.92) had taken Covaxin. Only 3 (2.9%) study participants had breakthrough infections and all these three participants had taken Covishield. Ninety-four (91.26%) of study participants had taken at least one dose of COVID-19 vaccine. A total of 62 (60.19%) participants had one or the other adverse reaction following vaccination. Only 3 (2.9%) study participants had breakthrough infections and all these three participants had taken Covishield. Conclusion: The given COVID-19 vaccines are safe and clinically efficacious with no statistically significant difference between the COVID-19 vaccine type and adverse reaction or with the incidence of breakthrough infection.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
